Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PositronPOSC +5.51%30 PB Ratio is 40.05 as of Jul. 31, 2026, which is 5% below its 10-year median of 42.03. GuruFocus rates POSC with a GF Score™ of 30/100 and a GF Value™ of $0.12 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Positron ranks worse than 98.35% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-31), Positron's share price is $1.762. Positron's Book Value per Share for the quarter that ended in Dec. 2025 was $0.04. Hence, Positron's PB Ratio of today is 40.05.
The historical rank and industry rank for Positron's PB Ratio or its related term are showing as below:
POSC'
s PB Ratio Range Over the Past 10 Years
Min: 34.09 Med: 42.03 Max: 56.78
Current: 44.05
During the past 13 years, Positron's highest PB Ratio was 56.78. The lowest was 34.09. And the median was 42.03.
POSC's PB Ratio is ranked worse than 98.35% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs POSC: 44.05
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Positron was 73.80% per year. The lowest was -62.20% per year. And the median was 26.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Positron PB Ratio Related Terms
Positron PB Ratio Historical Data
* Premium members only.
The historical data trend for Positron's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Positron's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Positron PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Positron's PB Ratio distribution charts can be found below:
* The bar in red indicates where Positron's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Positron's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Positron (POSC) has a PB Ratio of 40.05 as of Jul. 31, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Positron and its competitors. This is near median its historical median of 42.03. Over the past decade, Positron's PB Ratio has ranged from 34.09 to 56.78. According to the industry distribution chart, Positron ranks #774 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 98.3%.
Is Positron's PB Ratio too high?
Positron's current PB Ratio of 40.05 is near median its 10-year median of 42.03. Over the past 10 years, this metric has ranged from a low of 34.09 to a high of 56.78. The Medical Devices & Instruments industry median PB Ratio is 2.05. Positron's value of 40.05 is 1853.7% above this industry median. Based on the distribution chart, Positron ranks #774 out of 787 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Positron has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Positron's PB Ratio compare to MDAI and ECOR?
According to the Medical Devices & Instruments industry distribution chart, Positron ranks #774 out of 787 companies for PB Ratio. This places Positron in the lower half of its industry. The industry median PB Ratio is 2.05. Positron's value of 40.05 is 1853.7% above this benchmark. Historically, Positron's own PB Ratio has ranged from 34.09 to 56.78 over the past decade. While the company's 10-year median is 42.03 vs. the industry median of 2.05, Positron has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Positron's current PB Ratio of 40.05 is 1853.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Positron and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Positron's current PB Ratio is 40.05, which is near median its own 10-year median of 42.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Positron stock overvalued right now?
Based on GuruFocus' analysis, Positron (POSC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.12, compared to a current price of $1.76 — trading 1368.3% above its estimated fair value. The current PB Ratio is 40.05, which is near median its 10-year median of 42.03 and 1853.7% above the Medical Devices & Instruments industry median of 2.05. Positron's overall GF Score™ is 30/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Positron (POSC), the current PB Ratio is 40.05 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Positron (POSC) Overvalued in 2026?
Based on GuruFocus' analysis, Positron stock appears to be overvalued.
The current stock price of $1.76 is trading 1368.3% above its estimated GF Value™ of $0.12.
GuruFocus considers Positron to be Significantly Overvalued.
Key valuation signals for POSC:
PB Ratio: 40.05 (near median its 10-year median of 42.03)
GF Value™: $0.12 vs. price of $1.76 (1368.3% above fair value)
Industry Position: 1853.7% above the Medical Devices & Instruments median (#774 of 787)
No single metric tells the full story. See the POSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Positron Corp is a medical technology company engaged in the co-development, manufacture, and sale of PET and PET-CT imaging systems, delivering high-performance, cost-effective molecular imaging solutions that empower healthcare providers to improve the diagnosis and treatment of cardiovascular disease and other critical conditions. By combining proprietary PET and PET-CT systems with comprehensive clinical and technical support, flexible financing, & a focus on operational efficiency, Positron makes advance diagnostic imaging more accessible & sustainable for hospitals, outpatient centers, & physician practices. The company focused on advancing positron emission tomography imaging through the development, manufacture, & commercialization of PET & PET-computed tomography imaging systems.
30GF Score
Get the complete analysis for POSC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POSC has been successfully added to your 
